The oral, direct thrombin inhibitor H 376/95 reduced thrombus size in a deep venous thrombus treatment conscious rat model.

被引：0
|
作者：
Carlsson, S [1 ]
Adler, G [1 ]
Elg, M [1 ]
机构：
[1] AstraZeneca R&D, Molndal, Sweden
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
240
引用
收藏
页码：58A / 58A
页数：1
相关论文
共 20 条
  • [1] Effect of melagatran, the active form of the oral direct thrombin inhibitor, H 376/95, on platelet deposition and relative thrombus size in a porcine, coronary artery over-stretch injury model
    Schersten, F
    Wahlund, G
    Carlsson, S
    Mattsson, C
    Grip, L
    CIRCULATION, 2000, 102 (18) : 130 - 130
  • [2] Melagatran, the active form of the oral direct thrombin inhibitor, H 376/95, attenuates platelet deposition and relative thrombus size in a porcine, coronary artery over-stretch injury model
    Scherstén, F
    Wahlund, G
    Carlsson, S
    Mattsson, C
    Grip, L
    EUROPEAN HEART JOURNAL, 2000, 21 : 500 - 500
  • [3] The effects of melagatran, the active form of H 376/95, an oral, direct thrombin inhibitor, on thrombin generation.
    Bostrom, SL
    Sarich, TC
    Wolzt, M
    BLOOD, 2000, 96 (11) : 56A - 56A
  • [4] Antithrombotic effects of H 376/95, an oral direct thrombin inhibitor, in an ex vivo human model of arterial thrombosis.
    Sarich, TC
    Osende, JI
    Eriksson, UG
    Fager, GB
    Eriksson-Lepkowska, M
    Carlsson, S
    Gustafsson, D
    Badimon, JJ
    CIRCULATION, 2000, 102 (18) : 827 - 827
  • [5] Pharmacodynamic properties of H 376/95, a prodrug of the direct thrombin inhibitor melagatran, intended for oral use.
    Gustafsson, D
    Nystrom, JE
    Carlsson, S
    Bredberg, U
    Elg, M
    Gyzander, E
    Ungell, AL
    Antonson, T
    Hirsh, J
    BLOOD, 1999, 94 (10) : 26A - 26A
  • [6] Pharmacokinetics of H 376/95 (H): A novel oral direct thrombin inhibitor in patients undergoing total knee arthoplasty (TKA).
    Peters, G
    Whipple, J
    Eriksson, U
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P35 - P35
  • [7] Antithrombotic efficacy of an oral thrombin inhibitor (TI) in a conscious rat model of deep venous thrombosis (DVT) with and without aspirin (ASA).
    Wilson, A
    Smith, T
    Shuman, RT
    Kurz, KD
    BLOOD, 1995, 86 (10) : 350 - 350
  • [8] The direct thrombin inhibitor melagatran and its oral prodrug H 376/95:: Intestinal absorption properties, biochemical and pharmacodynamic effects
    Gustafsson, D
    Nyström, JE
    Carlsson, S
    Bredberg, U
    Eriksson, U
    Gyzander, E
    Elg, M
    Antonsson, T
    Hoffmann, KJ
    Ungell, AL
    Sörensen, H
    Någård, S
    Abrahamsson, A
    Bylund, R
    THROMBOSIS RESEARCH, 2001, 101 (03) : 171 - 181
  • [9] Influence of acetylsalicylic acid on the pharmacodynamics and pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor H376/95
    Fager, G
    Eriksson-Lepkowska, M
    Frison, L
    Bylock, A
    Ahnoff, M
    Eriksson, UG
    EUROPEAN HEART JOURNAL, 2000, 21 : 441 - 441
  • [10] Prothrombin time assays are unsuitable for monitoring the effects of melagatran, the active form of the oral, direct thrombin inhibitor H 376/95.
    Mattsson, C
    Menschik-Lundin, A
    BLOOD, 2000, 96 (11) : 98B - 98B
12